发布求助
文献互助 智能选刊 最新文献

Cancer clinical trials最新文献

筛选
英文 中文
Clinical implication of serial neurophysiologic study in diagnosis of chemotherapy induced peripheral neuropathy 系列神经生理学研究在化疗性周围神经病变诊断中的临床意义
Cancer clinical trials Pub Date : 2018-01-01 DOI: 10.4172/2529-797x-c1-003
Ousman Bajinka, Abdoulie O. Touray, O. Oyelakin
{"title":"Clinical implication of serial neurophysiologic study in diagnosis of chemotherapy induced peripheral neuropathy","authors":"Ousman Bajinka, Abdoulie O. Touray, O. Oyelakin","doi":"10.4172/2529-797x-c1-003","DOIUrl":"https://doi.org/10.4172/2529-797x-c1-003","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"03 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70317715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Review of Pulsed Reduced Dose Rate Re-irradiation for Recurrent Tumors 脉冲低剂量率再照射治疗复发肿瘤的研究进展
Cancer clinical trials Pub Date : 2018-01-01 DOI: 10.4172/2577-0535.1000143
K. Rogacki, S. Chao, Jennifer S. Yu, A. Godley, Eshan Balagamwala, J. Suh, E. Murphy
{"title":"Review of Pulsed Reduced Dose Rate Re-irradiation for Recurrent Tumors","authors":"K. Rogacki, S. Chao, Jennifer S. Yu, A. Godley, Eshan Balagamwala, J. Suh, E. Murphy","doi":"10.4172/2577-0535.1000143","DOIUrl":"https://doi.org/10.4172/2577-0535.1000143","url":null,"abstract":"Pulsed Reduced Dose Rate (PRDR) is an external beam re-irradiation technique that may be appropriate for recurrent tumors in patients who have previously undergone radiation treatment. PRDR is thought to effectively target dividing neoplastic cells that display Low-Dose Hyper-Radiosensitivity (LDHRS) while permitting sub-lethal damage repair in non-proliferating normal tissues. To date, only a few case reports and several retrospective studies have reported on efficacy after PRDR retreatment across several disease sites, including CNS, breast, and nasopharyngeal tumors. In this article, we review available publications of PRDR re-irradiation in patients. Taken together, this research demonstrates that PRDR offers a treatment option for large volume recurrent disease at previously irradiated sites. More research is needed to establish therapeutic benefit and late adverse effects for each disease site.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"41 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2577-0535.1000143","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix. 丝裂霉素c、博来霉素、长春新碱和顺铂治疗晚期复发性宫颈鳞状细胞癌。
Cancer clinical trials Pub Date : 1982-03-01 DOI: 10.1097/00006254-198203000-00025
D. Alberts, P. Martimbeau, E. Surwit, N. Oishi
{"title":"Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix.","authors":"D. Alberts, P. Martimbeau, E. Surwit, N. Oishi","doi":"10.1097/00006254-198203000-00025","DOIUrl":"https://doi.org/10.1097/00006254-198203000-00025","url":null,"abstract":"A combination chemotherapy regimen containing mitomycin-C (10 mg/m2, day 2), vincristine (0.5 mg/m2, days 1 and 4), bleomycin (30 U QD, days 1--4 as a continuous intravenous infusion during courses one and two only), and cis-platinum (50 mg/m2, days 1 and 22) was administered every 6 weeks to 14 evaluable patients with advanced (i.e., Stage IVB) and/or recurrent squamous cell carcinoma of the cervix. Four patients (29%) achieved a complete response, lasting 8, 9.5+, 17+, and 21+ months. Three of these patients have had complete disappearance of their pulmonary metastases and one has had resolution of a large left-sided pelvic wall mass. Two additional patients (14%) had a partial response to therapy, each lasting 1.5 months. The median survival for these 14 patients was 9.0 months. The chemotherapy regimen was well tolerated. There were no drug-related deaths and no instances of severe or irreversible renal dysfunction or peripheral neuropathy. The mean lowest white blood cell and platelet counts were 4540 and 205,000 per mm3, respectively. Although severe or life-threatening thrombocytopenia occurred in only 36% patients, it appeared to be the dose-limiting toxicity of this drug combination.","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3 1","pages":"313-6"},"PeriodicalIF":0.0,"publicationDate":"1982-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/00006254-198203000-00025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61936376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 45
Guidelines for radiation injury to bowel and bladder from external irradiation alone. 单纯外照射对肠道和膀胱的辐射损伤指南。
Cancer clinical trials Pub Date : 1981-01-01
H Nussbaum, A R Kagan, M Wollin, A Rao, B Hintz, H Gilbert, P Chan, J Winkley, D Kwan
{"title":"Guidelines for radiation injury to bowel and bladder from external irradiation alone.","authors":"H Nussbaum,&nbsp;A R Kagan,&nbsp;M Wollin,&nbsp;A Rao,&nbsp;B Hintz,&nbsp;H Gilbert,&nbsp;P Chan,&nbsp;J Winkley,&nbsp;D Kwan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Sixteen patients with intestinal and bladder injury secondary to external irradiation alone have been reviewed. Tolerance doses are shown to vary depending on the history of recent pelvic surgery, as compared to pelvic surgery in the past. A partial review of the literature and a discussion of the causative factors is presented.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3","pages":"295-9"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18299346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Carcinogenic, mutagenic, teratogenic workshop. 致癌、致突变、致畸车间。
Cancer clinical trials Pub Date : 1981-01-01
H Suit, E Hall, E Frei
{"title":"Carcinogenic, mutagenic, teratogenic workshop.","authors":"H Suit,&nbsp;E Hall,&nbsp;E Frei","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 Suppl ","pages":"37-41"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18319553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Conference on long-term normal tissue effects of cancer treatment: summary of cardiac portion of cardiopulmonary workshop. 癌症治疗对正常组织的长期影响会议:心肺研讨会心脏部分综述。
Cancer clinical trials Pub Date : 1981-01-01
{"title":"Conference on long-term normal tissue effects of cancer treatment: summary of cardiac portion of cardiopulmonary workshop.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 Suppl ","pages":"53-9"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18319555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cyclical combination chemotherapeutic regimen in adult soft tissue sarcoma. 成人软组织肉瘤的周期联合化疗方案。
Cancer clinical trials Pub Date : 1981-01-01
D N Dalley, J A Levi, R A Nesbitt, M H Tattersall, R L Woods, R M Fox, R S Aroney
{"title":"Cyclical combination chemotherapeutic regimen in adult soft tissue sarcoma.","authors":"D N Dalley,&nbsp;J A Levi,&nbsp;R A Nesbitt,&nbsp;M H Tattersall,&nbsp;R L Woods,&nbsp;R M Fox,&nbsp;R S Aroney","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A cyclical combination chemotherapeutic regimen of Adriamycin and cyclophosphamide alternating with actinomycin D and DTIC was administered to 20 evaluable patients with metastatic soft tissue sarcoma. Responses included four (20%) partial remissions and five (25%) patients with stable disease. There was a significant prolongation of survival for responding patients (median 42.5+ weeks) compared to patients with progressive disease (median 17.5 weeks). Principal toxicity was nausea and vomiting particularly with the actinomycin D/DTIC combination and four patients found this so intolerable they withdrew from study. These results are inferior to those reported for Adriamycin alone and other combinations. Further evaluation of the concept of sequential non-cross-resistant combinations would only seem appropriate if newer more active agents are identified and each combination is administered for a set duration before crossing over to the alternative regimen.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"163-5"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18263278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nodular lymphoma. Prolongation of survival by complete remission. 结节性淋巴瘤。通过完全缓解延长生存期。
Cancer clinical trials Pub Date : 1981-01-01
C H Diggs, P H Wiernik, S S Ostrow
{"title":"Nodular lymphoma. Prolongation of survival by complete remission.","authors":"C H Diggs,&nbsp;P H Wiernik,&nbsp;S S Ostrow","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Forty previously untreated patients with either nodular poorly differentiated lymphocytic or nodular mixed lymphocytic/histiocytic non-Hodgkin's lymphoma were evaluated for length of survival from the onset of combination chemotherapy. Complete remissions from initial therapy were achieved in 27/40 patients (67.5%). Actuarial analysis of survival shows that 83% of the complete responders from initial treatment are expected to be living at 7 years in contrast to a less than 2-year median survival of those who failed to reach complete remission with initial therapy when deaths from nonlymphomatous causes are excluded. Wilcoxon comparison of these curves shows a significant (p = 0.0001) advantage for those who are able to attain a complete remission. Treatment was not implicated in any death. Of those patients not reaching complete remission from initial therapy, 80% of the survivors attained a complete response from other therapy. It is concluded that complete remission attainment from initial chemotherapy significantly prolongs survival for patients with nodular lymphoma. Therefore, since combination chemotherapy has given higher complete remission rates than have single agents, such therapy offers the patient with nodular lymphoma the greatest chance for prolonged survival.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 2","pages":"107-14"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18264300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic factors in metastatic breast cancer. 转移性乳腺癌的预后因素。
Cancer clinical trials Pub Date : 1981-01-01
M F Fey, K W Brunner, R W Sonntag
{"title":"Prognostic factors in metastatic breast cancer.","authors":"M F Fey,&nbsp;K W Brunner,&nbsp;R W Sonntag","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Modern polychemotherapy has decisively changed the spontaneous course and median survival in metastatic stages of breast cancer. The prognosis for patients with the rather unfavorable type of visceral metastatic spread is definitely better now than 10 years ago. The influence of modern polychemotherapy on the survival and course of cases with mainly osseous metastases, however, is more limited. It seems that, in contrast to hormonal therapy, modern polychemotherapy alters the course of more aggressive types of metastases with a poor prognosis into a more favorable form of disease.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 3","pages":"237-47"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18297552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estrogen receptor protein and its correlation to recurrent breast cancer. A study of 213 patients at the Pennsylvania Hospital. 雌激素受体蛋白及其与复发性乳腺癌的关系。一项对宾夕法尼亚医院213名病人的研究。
Cancer clinical trials Pub Date : 1981-01-01
H J Lerner, E Marcovitz
{"title":"Estrogen receptor protein and its correlation to recurrent breast cancer. A study of 213 patients at the Pennsylvania Hospital.","authors":"H J Lerner,&nbsp;E Marcovitz","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The value of having estrogen receptor protein analysis is more widely appreciated, and the estrogen receptor determination at the time of biopsy or mastectomy is rapidly becoming a standard procedure. The patients with positive estrogen receptors (and progesterone receptors) are now identified as those who will respond to hormone ablation or manipulation. Some authors have stated that a positive estrogen receptor has a \"protective\" value against regional metastasis and early recurrence. At the time of biopsy, a portion of the tumor is frozen in liquid nitrogen and sent for estrogen receptor (and progesterone receptor) analysis. The 200 breast cancer patients had estrogen receptors performed with 118 estrogen receptors positive and 82 estrogen receptors negative. The following is an analysis of the 130 mastectomy patients. Negative nodes: ER+, 50; ER-, 20. One to three positive nodes: ER+, 23; ER-, 12. Four and more positive nodes: ER+, 15; ER-, 10. At the present time, the data is being correlated to the patient's age, the time of recurrence, and its relationship to estrogen receptors and progesterone receptors.</p>","PeriodicalId":75672,"journal":{"name":"Cancer clinical trials","volume":"4 1","pages":"17-9"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18228870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信